Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients

Journal of Antibiotics

Volumn 65, Issue 2, 2012, Pages 83-86

  Bozkurt Güzel, Çagla ^a   Gerçeker, Ayse Alev ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

antibiotic combinations; colistin; cystic fibrosis; post antibiotic effect (PAE); Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; COLISTIN;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG POTENTIATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; COLISTIN; CYSTIC FIBROSIS; DRUG THERAPY, COMBINATION; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

PSEUDOMONAS AERUGINOSA;

EID: 84857761473     PISSN: 00218820     EISSN: 18811469     Source Type: Journal    
DOI: 10.1038/ja.2011.101     Document Type: Article

References (29)

1. Miller, M. B. & Gilligan, P. H. Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis. J. Clin. Microbiol. 41, 4009-4015 (2003). (Pubitemid 37099657)
2. Nation, R. L. & Li, J. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22, 535-543 (2009).
3. Craig, W. A. & Gudmundsson, S. in Antibiotics in laboratory medicine. Postantibiotic effect. (ed Lorian, V.) 296-329 Lippincott Williams and Wilkins Co., Baltimore, 1996.
4. Craig, W. A. Pharmacokinetic/pharmacodynamic parameters: the rational for antibacterial dosing in mice and men. Clin. Infect. Dis. 26, 1-10 (1998).
5. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing, Eighteenth Informational Supplement, CLSI document M100-S18, CLSI, Wayne, Pennsylvania, USA, 2008.
6. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Seventh Approved Standard, CLSI document M7-A7, CLSI, Wayne, Pennsylvania, USA, 2006.
7. Pillai, S. K., Moellering, R. C. Jr. & Eliopoulos, G. M. in Antibiotics in laboratory medicine. Antimicrobial Combinations (ed Lorian, V.) 365-440 Lippincott Williams and Wilkins Co., Philadelphia, 2005.
8. Odds, F. C. Synergy, antagonism, and what the chequerboard puts between them. J. Antimicrob. Chemother. 52, 1 (2003). (Pubitemid 36850074)
9. Gunderson, B. W., Ross, G. H., Ibrahim, K. H. & Rotschafer, J. C. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21 (suppl 11), 302-318 (2001).
10. Howard, M., Frizell, R. & Bedwell, D. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2, 467-469 (1996). (Pubitemid 26191920)
11. Du, M. et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J. Mol. Med. 84, 573-582 (2006). (Pubitemid 43992849)
12. Li, J., Turnidge, J., Milne, R., Nation, R. L. & Coulthard, K. In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 45, 781-785 (2001). (Pubitemid 32182025)
13. Gunderson, B. W. et al. Synergistic activity of colistin and ceftazidime against multiantibiotic- resistant Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 47, 905-909 (2003). (Pubitemid 36254214)
14. Lu, Q. et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med. 36, 1147-1155 (2010).
15. Michalopoulos, A. et al. Aerosolized colistin for the treatment of nosocomial pneumonia due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Crit. Care. 9, R53-R59 (2005).
16. Ratjen, F. et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57, 306-311 (2006). (Pubitemid 43160174)
17. Giamarellou, H. & Poulakou, G. Multidrug-resistant gram-negative infections: what are the treatment options? Drugs 69, 1879-1901 (2009).
18. Santré, C. et al. Amikacin levels in bronchial secretions of 10 pneumonia patients with respiratory support treated once daily versus twice daily. Antimicrob. Agents Chemother. 39, 264-267 (1995).
19. Goldstein, I. et al. Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. Am. J. Respir. Crit. Care Med. 165, 171-175 (2002). (Pubitemid 34084452)
20. Döring, G. et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16, 749-767 (2000).
21. Giamarellos-Bourboulis, E. J., Xirouchaki, E. & Giamarellou, H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn. Microbiol. Infect. Dis. 40, 117-120 (2001). (Pubitemid 32735549)
22. Giamarellos-Bourboulis, E. J., Karnesis, L. & Giamarellou, H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn. Microbiol. Infect. Dis. 44, 259-263 (2002). (Pubitemid 35454100)
23. Giamarellos-Bourboulis, E. J., Sambatakou, H., Galani, I. & Giamarellou, H. In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa. J. Chemother. 15, 235-238 (2003). (Pubitemid 36819310)
24. Tascini, C., Ferranti, S., Messina, F. & Menichetti, F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin. Microbiol. Infect. 6, 690-691 (2000). (Pubitemid 34966100)
25. Güzel, C. B. & Gerçeker, A. A. In vitro activities of various antibiotics, alone and in combination with colistin methanesulfonate, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Chemotherapy 54, 147-151 (2008). (Pubitemid 351448602)
26. Gerceker, A. A. & Otuk, G. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa. Chemotherapy 41, 433-436 (1995).
27. Li, R. C. & Tang, M. C. Post-antibiotic effect induced by an antibiotic combination: influence of altered susceptibility to individual components. J. Antimicrob. Chemother. 55, 583-586 (2005). (Pubitemid 40542606)
28. Buxbaum, A. & Georgopoulos, A. Postantibiotic effect of ceftriaxone and gentamicin alone and in combination on Klebsiella pneumoniae, Pseudomonas aeruginosa and Streptococcus viridans. Infection 24, 459-464 (1996). (Pubitemid 27023094)
29. Giamarellos-Bourboulis, E. J. et al. Postantibiotic effect of antimicrobial combinations on multidrug-resistant Pseudomonas aeruginosa. Diagn. Microbiol. Infec. Dis. 51, 113-117 (2005). (Pubitemid 40215420)